CADE CLARK
DALLAS, TX
Browse related groups: TX Incyte Corporation All categories
This page merges CMS profile IDs: 11288097, 11419138 (associated profiles published by CMS for the same provider; see the provenance section below).
General Payments — all program years on this page
$2,192.04
- Category: General Payments
- Program years: PY2021–2024
- Record count: 90
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $785.72 across 36 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $785.72 | 36 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Incyte Corporation | $90.60 | 4 |
| GENZYME CORPORATION | $76.86 | 3 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $66.87 | 3 |
| Regeneron Healthcare Solutions, Inc. | $62.29 | 2 |
| SOBI, INC | $53.76 | 2 |
| Janssen Biotech, Inc. | $52.93 | 2 |
| ADC Therapeutics America, Inc. | $43.92 | 2 |
| SERVIER PHARMACEUTICALS LLC | $43.16 | 2 |
| Genmab U.S., Inc. | $42.12 | 2 |
| Mirati Therapeutics, Inc. | $39.41 | 2 |
| Rigel Pharmaceuticals, Inc. | $38.87 | 4 |
| Blueprint Medicines Corporation | $27.78 | 1 |
| Legend Biotech USA Inc. | $25.13 | 1 |
| Stemline Therapeutics Inc. | $24.68 | 1 |
| Karyopharm Therapeutics Inc. | $22.81 | 1 |
| Daiichi Sankyo Inc. | $22.51 | 1 |
| Merck Sharp & Dohme Corporation | $18.98 | 1 |
| GlaxoSmithKline, LLC. | $18.76 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $14.28 | 1 |
By program year
Records — PY2024 (36)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
- Merged CMS profile IDs: 11288097, 11419138
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.